Skip to main content

A phase 2 study of duvelisib, a dual PI3K(delta/gamma) inhibitor, in patients with PTCL


Verastem Oncology


TAP Partner

Project Term: October 29, 2018 - September 30, 2020

In October 2018, LLS began a partnership with Verastem to support two clinical trials, "A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)" and "A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas." Verastem sold its global commercial and development rights to COPIKTRA (duvelisib) to Secura Bio in September 2020. Secura Bio continues to develop duvelisib in PTCL as enrollment was recently completed in the Phase 2 PRIMO clinical trial evaluating the efficacy and safety of duvelisib in adult patients with histologically confirmed relapsed or refractory PTCL.

In December 2020, Copiktra (duvelisib) was included in the National Comprehensive Cancer Network® T-Cell Lymphoma Guidelines® for the treatment of all subtypes of PTCL. Clinical data that supported the NCCN Guidelines inclusion was presented during the 2021 ASH meeting.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects